Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP-012: Lenvatinib + Pembrolizumab + TACE vs TACE in non-metastatic unresectable hepatocellular carcinoma
jRCT2080225190Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Lenvatinib + Pembrolizumab + TACE with Placebo + TACE (2 arms). Started May 2020; status: completed.
02
Drugs
pembrolizumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2080225190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225190.